Aurora ($ASG) Unpacking the Debt Deal & Equity Kicker Options
Prio Brief (#4) Making Sense of the Three Debt Deal Alternatives (plus bonus information)
We are releasing an update on Aurora Spine Corporation ($ASG).
Here is a quick, comprehensive breakdown of the debt deal currently on the table. We’ve included our usual short overview of Aurora Spine to start, but if you already know the company, feel free to skip straight to the deal updates.
Priority Briefings. Investing is dynamic, so our research never sits still. We don’t just file a report and walk away; we maintain an active, ongoing dialogue with the key stakeholders and management teams of our holdings.
Think of these briefs as your “insider access” to those calls. We strip away the corporate speak to bring you the direct highlights and actionable updates. You’ll see exactly how the business is evolving in real-time, long before it hits the quarterly report.
This series is exclusively for 🧙♂️ Inner Circle members
None of the following should be construed as investment advice. Please consult a financial advisor before making any investment decision. You will find a full disclaimer at the end of this post.
🦴 Aurora Spine Corporation ($ASG)
Aurora is a medical technology disruptor focused on the $10 billion spinal implant market. While technically a Canadian-listed entity, it is headquartered in Carlsbad, California, and operates at the cutting edge of minimally invasive surgery (MIS).
They are essentially the precision engineers of the human back, replacing old-school, “one-size-fits-all” hardware with smart, regenerative implants that mimic a patient’s actual anatomy.
Current Tech
The company specializes in two breakthrough platforms designed to make spinal surgery faster, safer, and more effective:
DEXA Technology™: This is the world’s first bone-mimicking platform. Most spinal implants are too stiff for the bone they sit on, leading to “subsidence” (where the implant sinks). Aurora’s DEXA implants are 3D-printed to match a patient’s specific bone density, drastically reducing complications.
SiLO™ & SiLO-TFX™: These systems address Sacroiliac (SI) joint pain—a common cause of lower back issues. Using a “posterior” approach, they allow surgeons to stabilize the joint through a tiny incision, leading to faster recovery and less tissue damage.
Expansion
For years, Aurora was a development-stage company building its IP. In late 2024 and throughout 2025, the business reached a massive turning point:
Positive Cash Flow: In 2024, Aurora reported its first-ever positive annual EBITDAC, signaling that the business is no longer just “burning cash” but is now a self-sustaining growth machine.
Massive Adoption: As of mid-2025, the company surpassed 2,500 successful procedures for its SiLO platform and over 1,500 for its DEXA-C cervical system.
High-Margin Transition: They are aggressively shifting away from third-party products to their own proprietary hardware, which has pushed gross margins to a healthy 60%+.
Expanding the Pipeline: They recently launched DEXA-L (for the lumbar spine) and the AIRO™ Facet Fusion System, opening up huge new segments of the spine and pain management markets.
As the healthcare world moves toward “value-based care”—where hospitals are rewarded for better patient outcomes—Aurora Spine has built a significant competitive moat. With a library of over 15 patents and a direct sales force expanding across the US, they are becoming the go-to partner for surgeons who want “smarter” rather than “bigger” solutions.
If you want the full picture of the company and our deep dive into the 2026 outlook, check out our write-up:
